Iovance Biotherapeutics, Inc. (IOVA) Stock Price & How to Invest
Last updated July 2026
Short answer
IOVA is Iovance Biotherapeutics, a commercial-stage cell-therapy company whose FDA-approved melanoma treatment Amtagvi is scaling revenue fast, so it trades as a high-growth but still unprofitable biotech story rather than a stable earnings compounder.
IOVA stock price
As of 2026-07-16, Iovance Biotherapeutics, Inc. (IOVA) last closed at $4.77, up 113.9% over the past year. Over the past 52 weeks it has traded between $1.81 and $5.41.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Iovance Biotherapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Iovance Biotherapeutics, Inc. (IOVA) do?
Iovance Biotherapeutics (Nasdaq: IOVA) develops tumor-infiltrating lymphocyte (TIL) cell therapies, individualized treatments made from a patient's own immune cells. Its lead product, Amtagvi (lifileucel), became the first FDA-approved one-time T-cell therapy for a solid tumor when it was cleared for advanced melanoma, and the company also sells Proleukin, an interleukin-2 product used alongside TIL treatment. Iovance manufactures Amtagvi in-house at its Iovance Cell Therapy Center and has treated more than 1,500 patients across commercial and clinical use, with expanding regulatory approvals including a conditional nod in Australia.
The investment picture is a classic early-commercial biotech: revenue is growing quickly off a small base while the company is still losing money. Full-year 2025 product revenue was roughly $264 million and Iovance guided to about $350 million to $370 million for 2026, driven by Amtagvi adoption and improving gross margins. Against a market capitalization near $1.4 billion, the stock reflects expectations that the ramp continues, manufacturing scale lifts margins, and pipeline programs in lung cancer, endometrial cancer, and other tumors eventually broaden the franchise. The bull case rests on execution; the bear case is dilution, competition, and the operational complexity of individualized cell therapy.
What's driving Iovance Biotherapeutics, Inc. (IOVA)?
1. Amtagvi commercial ramp
Amtagvi is the core growth engine, with U.S. revenue climbing sharply quarter over quarter as more authorized treatment centers come online and referrals grow. Management pointed to record demand and raised full-year 2026 revenue guidance to roughly $350 million to $370 million. The pace of new patient starts and center activations is the metric that most directly moves the story.
2. In-house manufacturing and margin scale
Iovance now makes Amtagvi exclusively at its own Iovance Cell Therapy Center, and gross margin was around 41% in the first quarter of 2026 after one-time costs. Management expects margins to trend higher as volume rises and processes get more efficient. Because cell therapy is manufacturing-intensive, margin expansion is central to the path toward profitability.
3. Pipeline and label expansion
Beyond second-line melanoma, Iovance is pursuing lifileucel in earlier-line melanoma, non-small cell lung cancer, endometrial cancer, and soft tissue sarcoma, plus next-generation engineered TIL programs such as an IL-12 tethered candidate. New indications and geographies (including approval in Australia) widen the addressable market. Each successful readout or approval adds optionality to the base melanoma franchise.
4. Balance sheet and runway management
The company reported roughly $319 million in cash as of the first quarter of 2026 and has guided to a cash runway into 2028, supported at times by equity raises. Extending runway while scaling revenue reduces near-term financing pressure. How efficiently Iovance funds the gap to profitability shapes future dilution risk.
What are the risks to Iovance Biotherapeutics, Inc. (IOVA)?
Iovance remains unprofitable and has historically funded operations with stock sales, so ongoing dilution is a real risk to existing shareholders. Amtagvi is a complex, individualized therapy that requires surgery, lymphodepletion, and specialized centers, which can slow adoption and limit the eligible patient pool. Competition from other cell therapies and immuno-oncology approaches, including engineered TIL and CAR-T efforts, could pressure the franchise over time. Manufacturing disruptions, reimbursement hurdles, or clinical setbacks in pipeline programs would materially hurt the growth thesis. As a small-cap biotech, the shares are volatile and sensitive to guidance changes and trial data.
How is Iovance Biotherapeutics, Inc. (IOVA) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Iovance Biotherapeutics, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$285M
- FY2026 revenue guidance: ~$350M to $370M
- Market cap: ~$1.4B
- Cash (Q1 2026): ~$319M
- Q1 2026 net loss: ~$79M
- Q1 2026 gross margin: ~41%
Iovance trades at roughly five times trailing revenue, a multiple that reflects rapid growth expectations rather than current earnings, since the company is still posting net losses. Losses have been narrowing year over year as Amtagvi revenue scales and margins improve. Valuation ultimately hinges on whether the revenue ramp and margin expansion continue toward eventual profitability.
Who competes with Iovance Biotherapeutics, Inc. (IOVA)?
Cell and TIL therapy developers
Companies pursuing adoptive cell therapies for solid tumors, including engineered TIL efforts such as Obsidian Therapeutics' OBX-115, compete on efficacy, durability, and manufacturing. Iovance's first-mover FDA approval and in-house scale are its main differentiators here.
Melanoma immuno-oncology incumbents
Established melanoma treatments, particularly checkpoint inhibitors from large pharma such as Merck (Keytruda) and Bristol Myers Squibb (Opdualag), define the standard of care that Amtagvi is used after. These franchises shape which patients reach TIL therapy.
Broader cell-therapy platforms
CAR-T and other engineered cell-therapy players like Gilead's Kite and Novartis compete for oncology cell-therapy mindshare, infrastructure, and treatment-center capacity, even though most CAR-T products target blood cancers rather than solid tumors.
How to invest in Iovance Biotherapeutics, Inc. (IOVA)
There are three common ways to get IOVA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so IOVA sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where IOVA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Iovance Biotherapeutics, Inc. (IOVA)
IOVA is an execution-driven biotech bet on Amtagvi's ramp and pipeline, priced for growth while the company works toward profitability.
More on Iovance Biotherapeutics, Inc. (IOVA)
Whether IOVA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IOVA a buy?, and where the stock could go from here in the IOVA stock forecast.
For income investors, whether IOVA pays a dividend and how the payout looks is covered in does IOVA pay a dividend?
Build a basket around IOVA with Walnut
Use Iovance Biotherapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Iovance Biotherapeutics do?
+
Iovance develops and sells tumor-infiltrating lymphocyte (TIL) cell therapies, which are made from a patient's own immune cells. Its lead product, Amtagvi, treats advanced melanoma, and it also markets Proleukin, an interleukin-2 product used in the treatment regimen.
What is Amtagvi and why does it matter?
+
Amtagvi (lifileucel) is the first FDA-approved one-time T-cell therapy for a solid tumor, cleared for advanced melanoma after prior treatment. It is Iovance's primary revenue driver and the basis for expansion into other cancers and geographies.
Is Iovance profitable?
+
No. As of mid-2026 Iovance is still unprofitable, though its net loss has been narrowing. It reported a net loss of roughly $79 million in the first quarter of 2026, down from about $116 million a year earlier as revenue grew.
How much revenue does Iovance generate?
+
Full-year 2025 product revenue was roughly $264 million, and the company guided to about $350 million to $370 million for 2026. Trailing-twelve-month revenue sits near $285 million, split between Amtagvi and Proleukin.
What is Iovance's cash position and runway?
+
Iovance reported approximately $319 million in cash as of the first quarter of 2026 and has guided to a cash runway into 2028. It has periodically raised capital through equity sales to fund its commercial ramp and pipeline.
Who are Iovance's main competitors?
+
Competition includes other cell-therapy and TIL developers such as Obsidian Therapeutics, melanoma immuno-oncology incumbents like Merck and Bristol Myers Squibb, and broader cell-therapy platforms from Gilead's Kite and Novartis. Iovance's edge is its first-mover TIL approval and in-house manufacturing.
What are the biggest risks for IOVA investors?
+
Key risks include continued losses and potential shareholder dilution, the operational complexity of individualized cell therapy, competition, reimbursement and adoption hurdles, and the possibility of clinical or manufacturing setbacks. As a small-cap biotech, the stock is volatile.
Why is IOVA stock volatile?
+
IOVA is a small-cap, pre-profitability biotech whose value depends heavily on Amtagvi's sales trajectory, guidance updates, pipeline data, and financing decisions. That makes the shares sensitive to news and prone to large swings in either direction.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Iovance Biotherapeutics, Inc.'s investor relations page or your broker before making investment decisions.